Recently, China Council for Brand Development, China Appraisal Society, National Brand Office of Xinhua News Agency, etc. jointly released the Chinese Brand Valuation Report 2022. Jiangsu Hansoh Pharmaceutical Group Co., Ltd., the main business entity of Hansoh Pharmaceutical Group Company Limited, reported a brand value of RMB 27.388 billion, ranking third in the Pharmaceutical & Health Category and reaching a new high.
The annual Chinese Brand Valuation Report has been released for nine years. Following international and national standards and adhering to a “scientific, fair, open and generally accepted” basis, the report has become an important initiative to establish a brand valuation mechanism with Chinese characteristics, build up momentum for Chinese brands, and facilitate Chinese brands to go global.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma highly values brand building and strives to promote innovation and development through an excellent and comprehensive brand management system. By fully leveraging the leading role of branding in business operation, deeply implementing the strategy to grow business through branding, and continuously strengthening technological innovation and intellectual property protection, Hansoh Pharma has achieved impressive results in innovative R&D, quality management, market and service, CSR, etc., and has increased its brand influence and brand value year by year.
Always putting patients in the first place, Hansoh Pharma focuses on the treatment of major diseases in the fields of oncology, anti-infectives, CNS, metabolism and autoimmunity. With four R&D centers in Maryland of the U.S. and Shanghai, Lianyungang and Changzhou of China, Hansoh Pharma has successfully marketed six innovative drugs, and is conducting 40+ clinical trials on 25+ innovative drug projects at different clinical stages; successfully commercialized innovative drugs have become its main growth engine. Driven by the independent development + BD strategy, Hansoh Pharma is intensifying efforts to establish global presence in frontier new drug fields, build a global innovation ecosystem, and accelerate the entry of its independently-developed innovative products into the global market to benefit patients worldwide. Hansoh Pharma has been ranked among the world’s Top 100 Pharmaceutical Companies and China's Top Three Best Industrial Enterprises in Pharmaceutical R&D Pipeline for many consecutive years; in 2021, it was ranked among Jiangsu's Top 100 Excellent Brands in Brand Building.
Hansoh Pharma aims to build itself into a top brand in the world and lead high-quality development of Chinese brands. Looking ahead, it will give full play to its leading and exemplary role as an industry leader to help China's pharmaceutical industry innovate and develop globally and help Chinese brands establish global presence.
